Ropivacaine extended release - PainReform

Drug Profile

Ropivacaine extended release - PainReform

Alternative Names: PRF 110; PRF-110-oily solution

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PainReform
  • Class Amides; Local anaesthetics; Piperidines; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Postoperative pain

Most Recent Events

  • 18 Jul 2018 US FDA grants approval to conduct two pivotal phase III trials for extended release ropivacaine for Post-operative pain
  • 02 Jun 2016 PainReform plans a phase II trial for Postoperative pain in Israel (NCT02784327)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top